Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.

doi:10.1097/JTO.0b013e3181e0b954

中山醫學大學機構典藏 CSMUIR > 醫學院 > 醫學系 > 期刊論文 > Item 310902500/3839

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/3839

Title:	Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
Authors:	Wu, Ming-Fang;Hsiao, Yi-Min;Huang, Chuan-Fu;Huang, Yu-Hsin;Yang, Wan-Jung;Chan, Hsiu-Wen;Chang, Jinghua Tsai;Ko, Jiunn-Liang
Contributors:	中山醫學大學：醫學系
Keywords:	Biomarker;Lung cancer;Lipocalin-2;nm23-H1
Date:	2010
Issue Date:	2011-06-14T03:56:41Z (UTC)
ISSN:	1556-0864
Abstract:	BACKGROUND: Pemetrexed disodium (Alimta), LY231514, is an antifolate that is able to simultaneously inhibit the synthesis of purines and pyrimidines. Pemetrexed has been approved for first- and second-line treatment in patients with non-small cell lung cancer (NSCLC). However, there is still a lack of clinical biomarkers for predicting the therapeutic response to pemetrexed. The aim of this study is to establish new biomarkers for pemetrexed treatment in NSCLC. METHODS: Human NSCLC cell lines were exposed to pemetrexed. The antitumor effect was measured by growth inhibition with MTT assay and expression of cell cycle mediators with immunoblots. Using the Superarray cancer pathway gene array, 482 genes were screened for differential expression in A549 cells that were untreated or treated with pemetrexed. RESULTS: A549 cells exhibited sensitivity but H1355 cells showed resistance to pemetrexed. To investigate the mechanisms of responsiveness and nonresponsiveness to pemetrexed in these cell lines, we measured the expression levels of thymidylate synthase (TS), dihydrofolate reductase (DHFR), reduced folate carrier, and folylpoly-gamma-glutamate synthetase genes. TS, DHFR, and reduced folate carrier gene expressions were significantly reduced in A549 and H1355 cells. Pemetrexed caused cell cycle arrest in the G1 phase and S phase in H1355 and A549 cells, respectively. Significantly higher expressions of many genes, especially lipocalin-2 (Lcn-2) and nm23-H1 proteins, were noted in A549 cells treated with pemetrexed in comparison with untreated cells. Furthermore, reverse transcriptase polymerase chain reaction and Western blot showed that Lcn-2 and nm23-H1 expressions increase in response to pemetrexed treatment in a dose-responsive manner in pemetrexed-sensitive A549 cells but not in resistant H1355 cells. CONCLUSIONS: Our results indicated that downregulation of TS and DHFR genes and upregulation of p21, p27, Lcn-2, and nm23-H1 genes may serve as new biomarkers for predicting responsiveness to pemetrexed.
URI:	https://ir.csmu.edu.tw:8080/ir/handle/310902500/3839 http://dx.doi.org/10.1097/JTO.0b013e3181e0b954
Relation:	Journal of Thoracic Oncology,Issue: Volume 5(8), August 2010, pp 1143-1151
Appears in Collections:	[醫學系] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	341	View/Open

Loading...